Shanghai Henlius Biotech (HKSE:02696) Total Equity: HK$4,375 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02696 Shanghai Henlius Biotech Inc HKSE:02696
67 GF Score
Price HK$67.30
GF Value HK$30.91
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Henlius Biotech Total Equity?

Shanghai Henlius Biotech HKSE:02696 -1.10% 67 Total Equity is HK$4,375 Mil as of Dec. 2025. GuruFocus rates HKSE:02696 with a GF Score™ of 67/100 and a GF Value™ of HK$30.91 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Shanghai Henlius Biotech's total equity for the quarter that ended in Dec. 2025 was HK$4,375 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Shanghai Henlius Biotech Total Equity Historical Data

* Premium members only.

The historical data trend for Shanghai Henlius Biotech's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Henlius Biotech Total Equity Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only 2,812.30 1,827.32 2,397.89 3,217.56 4,375.23

Shanghai Henlius Biotech Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,397.89 2,775.61 3,217.56 3,725.31 4,375.23
HKSE:02696
67GF Score
Shanghai Henlius Biotech Inc HKSE:02696
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Henlius Biotech Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Shanghai Henlius Biotech's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=13655.61-9280.38
=4,375

Shanghai Henlius Biotech's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=13655.61-9280.38
=4,375

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$4,375 Mil mean?
Shanghai Henlius Biotech (HKSE:02696) has a Total Equity of HK$4,375 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Shanghai Henlius Biotech and its competitors.
Is Shanghai Henlius Biotech's Total Equity too high?
Shanghai Henlius Biotech's current Total Equity is HK$4,375 Mil. Overall, Shanghai Henlius Biotech has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Henlius Biotech's Total Equity compare to VRTX and REGN?
Shanghai Henlius Biotech's Total Equity of HK$4,375 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Shanghai Henlius Biotech and its competitors. Shanghai Henlius Biotech's current Total Equity is HK$4,375 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Henlius Biotech stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Henlius Biotech (HKSE:02696) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$30.91, compared to a current price of HK$67.30 — trading 117.7% above its estimated fair value. The current Total Equity is HK$4,375 Mil. Shanghai Henlius Biotech's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Shanghai Henlius Biotech (HKSE:02696), the current Total Equity is HK$4,375 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Henlius Biotech (HKSE:02696) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued. The current stock price of HK$67.30 is trading 117.7% above its estimated GF Value™ of HK$30.91. GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.

Key valuation signals for HKSE:02696:

  • Total Equity: HK$4,375 Mil
  • GF Value™: HK$30.91 vs. price of HK$67.30 (117.7% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02696 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Henlius Biotech Business Description

Other Exchanges 2E8:Germany
Address B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
67GF Score

Get the complete analysis for HKSE:02696

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$67.30
Price
HK$30.91
GF Value